Achondroplasia

Lancet

Volumn 370, Issue 9582, 2007, Pages 162-172

  Horton, William A ^a   Hall, Judith G ^b   Hecht, Jacqueline T ^c  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACHONDROPLASIA; COGNITIVE DEVELOPMENT; DWARFISM; GROWTH PLATE; HUMAN; LIFE EXPECTANCY; OBESITY; POINT MUTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR UPREGULATION; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 34447288267     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61090-3     Document Type: Review

References (171)

1. Oberklaid F., Danks D., Jensen F., Stace L., and Rosshandler S. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J Med Genet 16 (1979) 140-146
2. Shiang R., Thompson L., Zhu Y., et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78 (1994) 335-342
3. Kozma C. Dwarfs in ancient Egypt. Am J Med Genet A 140 (2006) 303-311
4. Bellus G., Hefferon T., Ortiz de Luna R., et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 56 (1995) 368-373
5. Rimoin D. The chondrodystrophies. Adv Hum Genet 5 (1975) 1-118
6. Superti-Furga A., and Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A 143 (2007) 1-18
7. Pauli R. Achondroplasia. In: Cassidy S., and Allanson J. (Eds). Management of genetic syndromes (2005), John Wiley & Sons, Hoboken, NJ, USA 13-29
8. Trotter T., and Hall J. Health supervision for children with achondroplasia. Pediatrics 116 (2005) 771-783
9. Hall J. The natural history of achondroplasia. In: Nicoletti B., Kopits S., Ascani E., and McKusick V. (Eds). Human achondroplasia-a multidisciplinary approach (1988), Plenum Press, New York 3-10
10. Rousseau F., Bonaventure J., Legeai-Mallet L., et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371 (1994) 252-254
11. Horton W. Recent milestones in achondroplasia research. Am J Med Genet A 140 (2006) 166-169
12. Martinez-Frias M., Cereijo A., Bermejo E., Lopez M., Sanchez M., and Gonzalo C. Epidemiological aspects of Mendelian syndromes in a Spanish population sample: I. Autosomal dominant malformation syndromes. Am J Med Genet 38 (1991) 622-625
13. Orioli I., Castilla E., and Barbosa-Neto J. The birth prevalence rates for the skeletal dysplasias. J Med Genet 23 (1986) 328-332
14. Stoll C., Dott B., Roth M., and Alembik Y. Birth prevalence rates of skeletal dysplasias. Clin Genet 35 (1989) 88-92
15. Tavormina P., Bellus G., Webster M., et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64 (1999) 722-731
16. Horton W., and Lunstrum G. Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev Endocr Metab Disord 3 (2002) 381-385
17. Spranger J., Brill P., and Poznanski A. Bone dysplasias: an atlas of genetic disorders of skeletal development. 2nd edn. (2002), Oxford University Press, New York
18. Langer Jr. L., Baumann P., and Gorlin R. Achondroplasia: clinical radiologic features with comment on genetic implications. Clin Pediatr (Phila) 7 (1968) 474-485
19. Murdoch J., Walker B., Hall J., Abbey H., Smith K., and McKusick V. Achondroplasia-a genetic and statistical survey. Ann Hum Genet 33 (1970) 227-244
20. Horton W. Molecular pathogenesis of achondroplasia. Growth, Genetics and Hormones 22 (2006) 49-54
21. Tavormina P., Shiang R., Thompson L., et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9 (1995) 321-328
22. Bellus G., McIntosh I., Smith E., et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10 (1995) 357-359
23. Rousseau F., Saugier P., Le Merrer M., et al. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat Genet 10 (1995) 11-12
24. Rousseau F., el Ghouzzi V., Delezoide A., et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 5 (1996) 509-512
25. Horton W. Fibroblast growth factor receptor 3 and the human chondrodysplasias. Curr Opin Pediatr 9 (1997) 437-442
26. Superti-Furga A., Eich G., Bucher H., et al. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 154 (1995) 215-219
27. Wilkin D., Szabo J., Cameron R., et al. Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet 63 (1998) 711-716
28. Steger K., Tetens F., Seitz J., Grothe C., and Bergmann M. Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium. Histochem Cell Biol 110 (1998) 57-62
29. Tiemann-Boege I., Navidi W., Grewal R., et al. The observed human sperm mutation frequency cannot explain the achondroplasia paternal age effect. Proc Natl Acad Sci USA 99 (2002) 14952-14957
30. Goriely A., McVean G., Rojmyr M., Ingemarsson B., and Wilkie A. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 301 (2003) 643-646
31. Goriely A., McVean G., van Pelt A., et al. Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia. Proc Natl Acad Sci USA 102 (2005) 6051-6056
32. Ornitz D., and Marie P. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16 (2002) 1446-1465
33. Hehr U., and Muenke M. Craniosynostosis syndromes: from genes to premature fusion of skull bones. Mol Genet Metab 68 (1999) 139-151
34. Muenke M., Gripp K., McDonald-McGinn D., et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet 60 (1997) 555-564
35. Naski M., Wang Q., Xu J., and Ornitz D. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13 (1996) 233-237
36. Colvin J., Bohne B., Harding G., McEwen D., and Ornitz D. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12 (1996) 390-397
37. Deng C., Wynshaw-Boris A., Zhou F., Kuo A., and Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84 (1996) 911-921
38. Webster M., and Donoghue D. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15 (1996) 520-527
39. Naski M., Colvin J., Coffin J., and Ornitz D. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125 (1998) 4977-4988
40. Chen L., Adar R., Yang X., et al. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest 104 (1999) 1517-1525
41. Garofalo S., Kliger-Spatz M., Cooke J., et al. Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J Bone Miner Res 14 (1999) 1909-1915
42. Wang Y., Spatz M., Kannan K., et al. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci USA 96 (1999) 4455-4460
43. Jang J., Shin K., and Park J. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61 (2001) 3541-3543
44. van Rhijn B., Lurkin I., Radvanyi F., Kirkels W., van der Kwast T., and Zwarthoff E. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
45. Chesi M., Brents L., Ely S., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97 (2001) 729-736
46. Hafner C., van Oers J., Hartmann A., et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 126 (2006) 2404-2407
47. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
48. Ornitz D., Xu J., Colvin J., et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271 (1996) 15292-15297
49. Ornitz D. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16 (2005) 205-213
50. Liu Z., Xu J., Colvin J., and Ornitz D. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 16 (2002) 859-869
51. Ohbayashi N., Shibayama M., Kurotaki Y., et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 16 (2002) 870-879
52. Mohammadi M., Olsen S., and Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin Struct Biol 15 (2005) 506-516
53. Eswarakumar V., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139-149
54. Shimizu A., Tada K., Shukunami C., et al. A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 276 (2001) 11031-11040
55. Mohammadi M., Schlessinger J., and Hubbard S. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 86 (1996) 577-587
56. Hart K., Robertson S., and Donoghue D. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 12 (2001) 931-942
57. Hadari Y., Gotoh N., Kouhara H., Lax I., and Schlessinger J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 98 (2001) 8578-8583
58. Kanai M., Goke M., Tsunekawa S., and Podolsky D. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem 272 (1997) 6621-6628
59. Su W., Kitagawa M., Xue N., et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386 (1997) 288-292
60. Legeai-Mallet L., Benoist-Lasselin C., Delezoide A., Munnich A., and Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273 (1998) 13007-13014
61. Sahni M., Ambrosetti D., Mansukhani A., Gertner R., Levy D., and Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13 (1999) 1361-1366
62. Hart K., Robertson S., Kanemitsu M., Meyer A., Tynan J., and Donoghue D. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19 (2000) 3309-3320
63. Choi D., Toledo-Aral J., Lin H., et al. Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways. J Biol Chem 276 (2001) 5116-5122
64. Murakami S., Balmes G., McKinney S., Zhang Z., Givol D., and de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18 (2004) 290-305
65. Zhang R., Murakami S., Coustry F., Wang Y., and de Crombrugghe B. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc Natl Acad Sci USA 103 (2006) 365-370
66. Minina E., Kreschel C., Naski M., Ornitz D., and Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 3 (2002) 439-449
67. Dailey L., Laplantine E., Priore R., and Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol 161 (2003) 1053-1066
68. Schulz S. C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides 26 (2005) 1024-1034
69. Bartels C., Bukulmez H., Padayatti P., et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75 (2004) 27-34
70. Miyazawa T., Ogawa Y., Chusho H., et al. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 143 (2002) 3604-3610
71. Krejci P., Masri B., Fontaine V., et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118 (2005) 5089-5100
72. You M., Li E., and Hristova K. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. Biochemistry 45 (2006) 5551-5556
73. Adar R., Monsonego-Ornan E., David P., and Yayon A. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17 (2002) 860-868
74. Bellus G., Spector E., Speiser P., et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67 (2000) 1411-1421
75. Lievens P., Roncador A., and Liboi E. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. J Mol Biol 357 (2006) 783-792
76. Monsonego-Ornan E., Adar R., Feferman T., Segev O., and Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20 (2000) 516-522
77. Cho J., Guo C., Torello M., et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101 (2004) 609-614
78. Ben-Zvi T., Yayon A., Gertler A., and Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 119 (2006) 380-387
79. Hughes S. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 45 (1997) 1005-1019
80. Yazaki N., Hosoi Y., Kawabata K., et al. Differential expression patterns of mRNAs for members of the fibroblast growth factor receptor family, FGFR-1-FGFR-4, in rat brain. J Neurosci Res 37 (1994) 445-452
81. Belluardo N., Wu G., Mudo G., Hansson A., Pettersson R., and Fuxe K. Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis. J Comp Neurol 379 (1997) 226-246
82. Claus P., and Grothe C. Molecular cloning and developmental expression of rat fibroblast growth factor receptor 3. Histochem Cell Biol 115 (2001) 147-155
83. Vidrich A., Buzan J., Ilo C., Bradley L., Skaar K., and Cohn S. Fibroblast growth factor receptor-3 is expressed in undifferentiated intestinal epithelial cells during murine crypt morphogenesis. Dev Dyn 230 (2004) 114-123
84. Lachman R. Neurologic abnormalities in the skeletal dysplasias: a clinical and radiological perspective. Am J Med Genet 69 (1997) 33-43
85. Nicoletti B., Kopits S., Ascani E., and McKusick V. Human achondroplasia-a multidisciplinary approach (1988), Plenum Press, New York
86. Kurtz A., Filly R., Wapner R., et al. In utero analysis of heterozygous achondroplasia: variable time of onset as detected by femur length measurements. J Ultrasound Med 5 (1986) 137-140
87. Cordone M., Lituania M., Bocchino G., Passamonti U., Toma P., and Camera G. Ultrasonographic features in a case of heterozygous achondroplasia at 25 weeks' gestation. Prenat Diagn 13 (1993) 395-401
88. Patel M., and Filly R. Homozygous achondroplasia: US distinction between homozygous, heterozygous, and unaffected fetuses in the second trimester. Radiology 196 (1995) 541-545
89. Mesoraca A., Pilu G., Perolo A., et al. Ultrasound and molecular mid-trimester prenatal diagnosis of de novo achondroplasia. Prenat Diagn 16 (1996) 764-768
90. Francomano C. GeneReviews: achondroplasia. http://genetests.org/servlet/access?db=geneclinics&site=gt&id=88 88891&key=apg9GZxAMVb9m&gry=&fcn=y&fw=hMJO&filename= /profiles/achondroplasia/index.html (accessed March 26, 2007).
91. Hall J., Horton W., Kelly T., and Scott C. Head growth in achondroplasia: use of ultrasound studies. Am J Med Genet 13 (1982) 105
92. Cohen Jr. M., Walker G., and Phillips C. A morphometric analysis of the craniofacial configuration in achondroplasia. J Craniofac Genet Dev Biol Suppl 1 (1985) 139-165
93. Berkowitz R., Grundfast K., Scott C., Saal H., Stern H., and Rosenbaum K. Middle ear disease in childhood achondroplasia. Ear Nose Throat J 70 (1991) 305-308
94. Beighton P., and Bathfield C. Gibbal achondroplasia. J Bone Joint Surg Br 63-B (1981) 328-329
95. Siebens A., Hungerford D., and Kirby N. Curves of the achondroplastic spine: a new hypothesis. Johns Hopkins Med J 142 (1978) 205-210
96. Kopits S. Thoracolumbular kyphosis and lumbosacral hyperlordosis in achondroplastic children. Basic Life Science 48 (1988) 241-255
97. Hall J. Kyphosis in achondroplasia: probably preventable. J Pediatr 112 (1988) 166-167
98. Pauli R., Breed A., Horton V., Glinski L., and Reiser C. Prevention of fixed, angular kyphosis in achondroplasia. J Pediatr Orthop 17 (1997) 726-733
99. Reid C., Pyeritz R., Kopits S., et al. Cervicomedullary compression in young patients with achondroplasia: value of comprehensive neurologic and respiratory evaluation. J Pediatr 110 (1987) 522-530
100. Pauli R., Horton V., Glinski L., and Reiser C. Prospective assessment of risks for cervicomedullary-junction compression in infants with achondroplasia. Am J Hum Genet 56 (1995) 732-744
101. Ruiz-Garcia M., Tovar-Baudin A., Del Castillo-Ruiz V., et al. Early detection of neurological manifestations in achondroplasia. Childs Nerv Syst 13 (1997) 208-213
102. Keiper Jr. G., Koch B., and Crone K. Achondroplasia and cervicomedullary compression: prospective evaluation and surgical treatment. Pediatr Neurosurg 31 (1999) 78-83
103. Bellus G., Escallon C., Ortiz de Luna R., et al. First-trimester prenatal diagnosis in couple at risk for homozygous achondroplasia. Lancet 344 (1994) 1511-1512
104. Gooding H., Boehm K., Thompson R., Hadley D., Francomano C., and Biesecker B. Issues surrounding prenatal genetic testing for achondroplasia. Prenat Diagn 22 (2002) 933-940
105. Hecht J., Butler I., and Scott Jr. C. Long-term neurological sequelae in achondroplasia. Eur J Pediatr 143 (1984) 58-60
106. Hunter A., Bankier A., Rogers J., Sillence D., and Scott Jr. C. Medical complications of achondroplasia: a multicentre patient review. J Med Genet 35 (1998) 705-712
107. Hecht J., Francomano C., Horton W., and Annegers J. Mortality in achondroplasia. Am J Hum Genet 41 (1987) 454-464
108. Horton W., Rotter J., Rimoin D., Scott C., and Hall J. Standard growth curves for achondroplasia. J Pediatr 93 (1978) 435-438
109. Hunter A., Hecht J., and Scott Jr. C. Standard weight for height curves in achondroplasia. Am J Med Genet 62 (1996) 255-261
110. Hunter A., Reid C., Pauli R., and Scott Jr. C. Standard curves of chest circumference in achondroplasia and the relationship of chest circumference to respiratory problems. Am J Med Genet 62 (1996) 91-97
111. Hecht J., Horton W., Reid C., Pyeritz R., and Chakraborty R. Growth of the foramen magnum in achondroplasia. Am J Med Genet 32 (1989) 528-535
112. Hecht J., Nelson F., Butler I., et al. Computerized tomography of the foramen magnum: achondroplastic values compared to normal standards. Am J Med Genet 20 (1985) 355-360
113. Kao S., Waziri M., Smith W., Sato Y., Yuh W., and Franken Jr. E. MR imaging of the craniovertebral junction, cranium, and brain in children with achondroplasia. Am J Roentgenol 153 (1989) 565-569
114. Bruhl K., Stoeter P., Wietek B., et al. Cerebral spinal fluid flow, venous drainage and spinal cord compression in achondroplastic children: impact of magnetic resonance findings for decompressive surgery at the cranio-cervical junction. Eur J Pediatr 160 (2001) 10-20
115. Steinbok P., Hall J., and Flodmark O. Hydrocephalus in achondroplasia: the possible role of intracranial venous hypertension. J Neurosurg 71 (1989) 42-48
116. Dennis J., Rosenberg H., and Alvord Jr. E. Megalencephaly, internal hydrocephalus and other neurological aspects of achondroplasia. Brain 84 (1961) 427-445
117. Pierre-Kahn A., Hirsch J., Renier D., Metzger J., and Maroteaux P. Hydrocephalus and achondroplasia. A study of 25 observations. Childs Brain 7 (1980) 205-219
118. Reynolds K., Modaff P., and Pauli R. Absence of correlation between infantile hypotonia and foramen magnum size in achondroplasia. Am J Med Genet 101 (2001) 40-45
119. Thomas I., Frias J., Williams J., and Friedman W. Magnetic resonance imaging in the assessment of medullary compression in achondroplasia. Am J Dis Child 142 (1988) 989-992
120. Ho N., Guarnieri M., Brant L., et al. Living with achondroplasia: quality of life evaluation following cervico-medullary decompression. Am J Med Genet A 131 (2004) 163-167
121. Boor R., Fricke G., Bruhl K., and Spranger J. Abnormal subcortical somatosensory evoked potentials indicate high cervical myelopathy in achondroplasia. Eur J Pediatr 158 (1999) 662-667
122. Pauli R., Scott C., Wassman Jr. E., et al. Apnea and sudden unexpected death in infants with achondroplasia. J Pediatr 104 (1984) 342-348
123. Rimoin D. Cervicomedullary junction compression in infants with achondroplasia: when to perform neurosurgical decompression. Am J Hum Genet 56 (1995) 824-827
124. Wang H., Rosenbaum A., Reid C., Zinreich S., and Pyeritz R. Pediatric patients with achondroplasia: CT evaluation of the craniocervical junction. Radiology 164 (1987) 515-519
125. Colamaria V., Mazza C., Beltramello A., et al. Irreversible respiratory failure in an achondroplastic child: the importance of an early cervicomedullary decompression, and a review of the literature. Brain Dev 13 (1991) 270-279
126. Elwood E., Burstein F., Graham L., Williams J., and Paschal M. Midface distraction to alleviate upper airway obstruction in achondroplastic dwarfs. Cleft Palate Craniofac J 40 (2003) 100-103
127. Nelson F., Hecht J., Horton W., Butler I., Goldie W., and Miner M. Neurological basis of respiratory complications in achondroplasia. Ann Neurol 24 (1988) 89-93
128. Stokes D., Phillips J., Leonard C., et al. Respiratory complications of achondroplasia. J Pediatr 102 (1983) 534-541
129. Stokes D., Pyeritz R., Wise R., Fairclough D., and Murphy E. Spirometry and chest wall dimensions in achondroplasia. Chest 93 (1988) 364-369
130. Stokes D., Wohl M., Wise R., Pyeritz R., and Fairclough D. The lungs and airways in achondroplasia. Do little people have little lungs?. Chest 98 (1990) 145-152
131. Tasker R., Dundas I., Laverty A., Fletcher M., Lane R., and Stocks J. Distinct patterns of respiratory difficulty in young children with achondroplasia: a clinical, sleep, and lung function study. Arch Dis Child 79 (1998) 99-108
132. Waters K., Everett F., Sillence D., Fagan E., and Sullivan C. Breathing abnormalities in sleep in achondroplasia. Arch Dis Child 69 (1993) 191-196
133. Waters K., Everett F., Sillence D., Fagan E., and Sullivan C. Treatment of obstructive sleep apnea in achondroplasia: evaluation of sleep, breathing, and somatosensory-evoked potentials. Am J Med Genet 59 (1995) 460-466
134. Zucconi M., Weber G., Castronovo V., et al. Sleep and upper airway obstruction in children with achondroplasia. J Pediatr 129 (1996) 743-749
135. Mogayzel Jr. P., Carroll J., Loughlin G., Hurko O., Francomano C., and Marcus C. Sleep-disordered breathing in children with achondroplasia. J Pediatr 132 (1998) 667-671
136. Sisk E., Heatley D., Borowski B., Leverson G., and Pauli R. Obstructive sleep apnea in children with achondroplasia: surgical and anesthetic considerations. Otolaryngol Head Neck Surg 120 (1999) 248-254
137. Kopits S. Genetics clinics of The Johns Hopkins Hospital. Surgical intervention in achondroplasia. Correction of bowleg deformity in achondroplasia. Johns Hopkins Med J 146 (1980) 206-209
138. Stanley G., McLoughlin S., and Beals R. Observations on the cause of bowlegs in achondroplasia. J Pediatr Orthop 22 (2002) 112-116
139. Hamamci N., Hawran S., and Biering-Sorensen F. Achondroplasia and spinal cord lesion. Three case reports. Paraplegia 31 (1993) 375-379
140. Pyeritz R., Sack Jr. G., and Udvarhelyi G. Thoracolumbosacral laminectomy in achondroplasia: long-term results in 22 patients. Am J Med Genet 28 (1987) 433-444
141. Hecht J., Hood O., Schwartz R., Hennessey J., Bernhardt B., and Horton W. Obesity in achondroplasia. Am J Med Genet 31 (1988) 597-602
142. Allanson J., and Hall J. Obstetric and gynecologic problems in women with chondrodystrophies. Obstet Gynecol 67 (1986) 74-78
143. Berkowitz I., Raja S., Bender K., and Kopits S. Dwarfs: pathophysiology and anesthetic implications. Anesthesiology 73 (1990) 739-759
144. Hecht J., Thompson N., Weir T., Patchell L., and Horton W. Cognitive and motor skills in achondroplastic infants: neurologic and respiratory correlates. Am J Med Genet 41 (1991) 208-211
145. Todorov A., Scott Jr. C., Warren A., and Leeper J. Developmental screening tests in achondroplastic children. Am J Med Genet 9 (1981) 19-23
146. Brinkmann G., Schlitt H., Zorowka P., and Spranger J. Cognitive skills in achondroplasia. Am J Med Genet 47 (1993) 800-804
147. Fowler E., Glinski L., Reiser C., Horton V., and Pauli R. Biophysical bases for delayed and aberrant motor development in young children with achondroplasia. J Dev Behav Pediatr 18 (1997) 143-150
148. Roizen N., Ekwo E., and Gosselink C. Comparison of education and occupation of adults with achondroplasia with same-sex sibs. Am J Med Genet 35 (1990) 257-260
149. Thompson N., Hecht J., Bohan T., et al. Neuroanatomic and neuropsychological outcome in school-age children with achondroplasia. Am J Med Genet 88 (1999) 145-153
150. Gollust S., Thompson R., Gooding H., and Biesecker B. Living with achondroplasia in an average-sized world: an assessment of quality of life. Am J Med Genet A 120 (2003) 447-458
151. Mahomed N., Spellmann M., and Goldberg M. Functional health status of adults with achondroplasia. Am J Med Genet 78 (1998) 30-35
152. Horton W., Hecht J., Hood O., Marshall R., Moore W., and Hollowell J. Growth hormone therapy in achondroplasia. Am J Med Genet 42 (1992) 667-670
153. Kanaka-Gantenbein C. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton). J Pediatr Endocrinol Metab 14 (2001) 17-26
154. Kodama H., Okabe I., and Yanagisawa M. Therapeutic benefit of growth hormone in achrondroplastic dwarfism. Acta Paediatr Jpn 32 (1990) 323-324
155. Nishi Y., Kajiyama M., Miyagawa S., Fujiwara M., and Hamamoto K. Growth hormone therapy in achondroplasia. Acta Endocrinol (Copenh) 128 (1993) 394-396
156. Okabe T., Nishikawa K., Miyamori C., and Sato T. Growth-promoting effect of human growth hormone on patients with achondroplasia. Acta Paediatr Jpn 33 (1991) 357-362
157. Seino Y., Yamanaka Y., Shinohara M., et al. Growth hormone therapy in achondroplasia. Horm Res 53 suppl 3 (2000) 53-56
158. Shohat M., Tick D., Barakat S., Bu X., Melmed S., and Rimoin D. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 81 (1996) 4033-4037
159. Stamoyannou L., Karachaliou F., Neou P., Papataxiarchou K., Pistevos G., and Bartsocas C. Growth and growth hormone therapy in children with achondroplasia: a two-year experience. Am J Med Genet 72 (1997) 71-76
160. Weber G., Prinster C., Meneghel M., et al. Human growth hormone treatment in prepubertal children with achondroplasia. Am J Med Genet 61 (1996) 396-400
161. Aldegheri R., and Dall'Oca C. Limb lengthening in short stature patients. J Pediatr Orthop B 10 (2001) 238-247
162. Aldegheri R., Trivella G., Renzi-Brivio L., Tessari G., Agostini S., and Lavini F. Lengthening of the lower limbs in achondroplastic patients. A comparative study of four techniques. J Bone Joint Surg Br 70 (1988) 69-73
163. Ganel A., and Horoszowski H. Limb lengthening in children with achondroplasia. Differences based on gender. Clin Orthop Relat Res 332 (1996) 179-183
164. Lavini F., Renzi-Brivio L., and de Bastiani G. Psychologic, vascular, and physiologic aspects of lower limb lengthening in achondroplastics. Clin Orthop Relat Res 250 (1990) 138-142
165. Saleh M., and Burton M. Leg lengthening: patient selection and management in achondroplasia. Orthop Clin North Am 22 (1991) 589-599
166. Vilarrubias J., Ginebreda I., and Jimeno E. Lengthening of the lower limbs and correction of lumbar hyperlordosis in achondroplasia. Clin Orthop Relat Res 250 (1990) 143-149
167. Aviezer D., Golembo M., and Yayon A. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia-genetic short limbed dwarfism. Curr Drug Targets 4 (2003) 353-365
168. Rauchenberger R., Borges E., Thomassen-Wolf E., et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 278 (2003) 38194-38205
169. Yasoda A., Komatsu Y., Chusho H., et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10 (2004) 80-86
170. Potter L., Abbey-Hosch S., and Dickey D. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Rev 27 (2006) 47-72
171. Simsic J., Scheurer M., Tobias J., et al. Perioperative effects and safety of nesiritide following cardiac surgery in children. J Intensive Care Med 21 (2006) 22-26